SCHEMBL3497394

SCHEMBL3497394

O=C(O)c1cn2c(-c3ccc(Cl)cc3)cccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPP1CA P62136 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
RPA1 P27694 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
JAK1 P23458 3/20 0.43
JAK2 O60674 1/20 0.43
EGLN2 Q96KS0 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PIK3C3 Q8NEB9 1/20 0.41
FYN P06241 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498136 0.81 GAA (0.65) PTGS2GABRA2GABRB2
SCHEMBL119204 0.79 PTGS1 (0.51) PTGS1PTGS2GABRA2GABRB2
SCHEMBL3498219 0.76 SMN1; SMN2 (0.47) PPP1CARPA1SMN1; SMN2GABRA2GABRB2
SCHEMBL9753622 0.73 PTGS1 (0.53) PTGS1PTGS2MEN1KMT2AATM
SCHEMBL3035988 0.72 PTGS1 (0.51) PTGS1PTGS2JAK2KMT2A
SCHEMBL3306389 0.72 PTGS1 (0.51) PTGS1PTGS2KMT2AATM
SCHEMBL119926 0.72 GAA (0.66) L3MBTL1SMN1; SMN2PTGS1PTGS2MEN1
SCHEMBL3498537 0.72 EGLN1 (0.67) PTGS1PTGS2GABRA2GABRB2
SCHEMBL15418821 0.71 PTGS1 (0.41) L3MBTL1PTGS1PTGS2
SCHEMBL8610010 0.71 PTGS1 (0.41) PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 PPP1CA 4749/4885L3MBTL1 4412/4885RPA1 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.